AR132064A1 - Anticuerpos anti-cldn6 y métodos de uso - Google Patents
Anticuerpos anti-cldn6 y métodos de usoInfo
- Publication number
- AR132064A1 AR132064A1 ARP240100554A ARP240100554A AR132064A1 AR 132064 A1 AR132064 A1 AR 132064A1 AR P240100554 A ARP240100554 A AR P240100554A AR P240100554 A ARP240100554 A AR P240100554A AR 132064 A1 AR132064 A1 AR 132064A1
- Authority
- AR
- Argentina
- Prior art keywords
- antigen
- antibody
- binding fragment
- binding
- nucleic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente divulgación proporciona anticuerpos y fragmentos de unión a antígeno de los mismos que se unen a CLDN6 humanos, una composición farmacéutica que comprende dicho anticuerpo o fragmentos de unión a antígeno de los mismos, y el uso del anticuerpo o fragmentos de unión a antígeno de los mismos o la composición para tratar una enfermedad, como el cáncer. Reivindicación 1: Un anticuerpo o fragmento de unión a antígeno del mismo, que comprende un dominio de unión a antígeno que se une específicamente a la claudina 6 humana (CLDN6). Reivindicación 18: Una composición farmacéutica que comprende el anticuerpo o fragmento de unión a antígeno, de acuerdo con cualquiera de las reivindicaciones 1 a 17 que comprende además un portador farmacéuticamente aceptable. Reivindicación 28: Un ácido nucleico aislado que codifica el anticuerpo o fragmento de unión a antígeno de acuerdo con cualquiera de las reivindicaciones 1 a 17. Reivindicación 29: Un vector que comprende el ácido nucleico de acuerdo con la reivindicación 28. Reivindicación 30: Una célula huésped que comprende el ácido nucleico de acuerdo con la reivindicación 28 o el vector de acuerdo con la reivindicación 29. Reivindicación 31: Un procedimiento para producir un anticuerpo o un fragmento de unión a antígeno del mismo que comprende cultivar la célula huésped de acuerdo con la reivindicación 30 y recuperar el anticuerpo o el fragmento de unión a antígeno del cultivo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2023079815 | 2023-03-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR132064A1 true AR132064A1 (es) | 2025-05-21 |
Family
ID=90363964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240100554A AR132064A1 (es) | 2023-03-06 | 2024-03-05 | Anticuerpos anti-cldn6 y métodos de uso |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR132064A1 (es) |
| TW (1) | TW202436354A (es) |
| WO (1) | WO2024184812A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119462928B (zh) * | 2024-11-08 | 2025-09-05 | 深圳豪石生物科技有限公司 | 特异性靶向cldn6的抗体及其在制备car-t细胞中的应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| WO1993011161A1 (en) | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| EP1589107B1 (en) | 1992-08-21 | 2009-12-23 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| ATE204325T1 (de) | 1993-04-29 | 2001-09-15 | Unilever Nv | Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae |
| CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック，インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6602684B1 (en) | 1998-04-20 | 2003-08-05 | Glycart Biotechnology Ag | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
| EP2270150B2 (en) | 1999-04-09 | 2019-08-07 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| ATE430580T1 (de) | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| EP2439273B1 (en) | 2005-05-09 | 2019-02-27 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| RU2515108C2 (ru) | 2005-08-19 | 2014-05-10 | Эббви Инк | Иммуноглобулин с двойными вариабельными доменами и его применения |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| CA2694488A1 (en) | 2007-07-31 | 2009-02-05 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
| BR112012027001A2 (pt) | 2010-04-23 | 2016-07-19 | Genentech Inc | produção de proteínas heteromultiméricas |
| EP3421496B1 (en) * | 2011-05-13 | 2024-08-07 | Astellas Pharma Inc. | Antibodies for treatment of cancer expressing claudin 6 |
| KR102264570B1 (ko) | 2012-11-28 | 2021-06-14 | 자임워크스 인코포레이티드 | 가공된 면역글로불린 중쇄-경쇄 쌍 및 이들의 용도 |
| IL296026B2 (en) | 2013-09-13 | 2024-10-01 | Beigene Switzerland Gmbh | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
| BR112016027888A2 (pt) | 2014-05-28 | 2017-10-24 | Zymeworks Inc | construto de polipeptídeo de ligação ao antígeno isolado, polinucleotídeo isolado ou um conjunto de polinucleotídeos isolados, vetor ou conjunto de vetores, célula isolada, composição farmacêutica, uso do construto, método para tratar um sujeito com uma doença ou distúrbio, método para obter um construto, método para preparar um construto, meio de armazenamento legível por computador, método para produzir um construto de polipeptídeo de ligação com antígeno bi-específico e método para preparar um construto de polipeptídeo de ligação com antígeno isolado |
| CN116396393A (zh) | 2015-10-08 | 2023-07-07 | 酵活英属哥伦比亚省公司 | 包含κ和λ轻链的抗原结合多肽构建体及其用途 |
| AU2017317227B2 (en) | 2016-08-26 | 2024-08-01 | Beigene, Ltd. | Anti-Tim-3 antibodies and use thereof |
| TWI816729B (zh) | 2017-12-30 | 2023-10-01 | 英屬開曼群島商百濟神州有限公司 | 抗tigit抗體及其作為治療和診斷的用途 |
| JP7489922B2 (ja) | 2018-05-23 | 2024-05-24 | ベイジーン リミテッド | 抗ｏｘ４０抗体及び使用方法 |
| JP2024511319A (ja) * | 2021-03-09 | 2024-03-13 | ゼンコア インコーポレイテッド | Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体 |
-
2024
- 2024-03-05 AR ARP240100554A patent/AR132064A1/es unknown
- 2024-03-05 TW TW113107891A patent/TW202436354A/zh unknown
- 2024-03-05 WO PCT/IB2024/052127 patent/WO2024184812A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| TW202436354A (zh) | 2024-09-16 |
| WO2024184812A1 (en) | 2024-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR111203A1 (es) | Inmunoconjugados | |
| CO2021006248A2 (es) | Anticuerpos anti-nkg2a y usos de los mismos | |
| PE20220142A1 (es) | Anticuerpos de cadena pesada que se unen al psma | |
| EA201791961A1 (ru) | Антитела, специфичные к cd47 и pd-l1 | |
| MX2024006968A (es) | Anticuerpos cdh17 y metodos de tratamiento del cancer. | |
| BR112022017174A2 (pt) | Anticorpo monoclonal isolado, ou uma porção de ligação ao antígeno do mesmo, nucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica e métodos de tratamento de uma doença alérgica e de um tumor | |
| IL273578B1 (en) | Antibodies targeting pdl1 and methods of use thereof | |
| MX2022011951A (es) | Anticuerpos de la lectina 15 similar a la inmunoglobulina que se une a acido sialico (siglec15) y usos de los mismos. | |
| AR127271A1 (es) | Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos | |
| AR123537A1 (es) | Anticuerpo contra hla-dq2.5 y su uso para el tratamiento de la enfermedad celíaca | |
| AR132064A1 (es) | Anticuerpos anti-cldn6 y métodos de uso | |
| BR112023020371A2 (pt) | Anticorpo anti-adgre2 humanizado ou fragmento de ligação ao antígeno do mesmo, método de tratamento de um câncer, composição farmacêutica, sequência de ácido nucleico, vetor, célula isolada, e, método de tratamento de câncer | |
| BR112023021426A2 (pt) | Anticorpos de ligação a trop2 e usos dos mesmos | |
| CL2023003244A1 (es) | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos | |
| MX2023014866A (es) | Direccionamiento selectivo de celulas alorreactivas cd70+ huesped para prolongar la persistencia de las celulas t con car alogenicas. | |
| EA202092122A1 (ru) | Антитела против tip-1 и их применения | |
| AR131528A1 (es) | Anticuerpos anti-b7h3 y métodos de uso | |
| AR132063A1 (es) | Anticuerpos multiespecíficos anti-cldn6 y anti-cd3 y métodos de uso | |
| AR132062A1 (es) | Anticuerpos multiespecíficos anti-cd3 y métodos de uso | |
| AR132040A1 (es) | Anticuerpos muc1 y cd16a y métodos de uso | |
| AR132041A1 (es) | Anticuerpos cd16a y métodos de uso | |
| AR131527A1 (es) | Anticuerpos anti-b7h3 y métodos de uso | |
| AR130129A1 (es) | Constructos de unión a cd98 para tratar tumores cerebrales | |
| AR130172A1 (es) | Anticuerpos anti-pvrig y métodos de uso | |
| PE20251175A1 (es) | Anticuerpos anti-bmp9 y metodos de uso de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |